Sanofi-Aventis closes acquisition of Merial
This article was originally published in Scrip
Sanofi-Aventis has completed its $4 billion cash acquisition of the 50% interest in Merial that it did not already own. It acquired the stake from its joint venture partner Merck & Co, which was required to sell the stake for antitrust reasons linked to its purchase of Schering-Plough (scripnews.com, July 31st, 2009).
You may also be interested in...
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.